Genta Withdraws NDA For Genasense In Melanoma
This article was originally published in The Pink Sheet Daily
Executive Summary
The company has requested a meeting with FDA to identify the next steps for further development. The move coincides with a restructuring at Genta to focus resources on the Genasense program.
You may also be interested in...
Abbott Taps Genentech Oncology Expertise For Two Phase I Compounds
Drug makers will collaborate on research and development of a Bcl-2 protein antagonist and VEGFR-based kinase inhibitor.
Abbott Taps Genentech Oncology Expertise For Two Phase I Compounds
Drug makers will collaborate on research and development of a Bcl-2 protein antagonist and VEGFR-based kinase inhibitor.
Genta Targeting Year-End Genasense NDA In Myeloma Or Lymphocytic Leukemia
The NDA will be based on either a 224-patient myeloma study or a 241-patient CLL study. Genta says that it has received helpful feedback from FDA since withdrawing a Genasense NDA for melanoma.